Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy

Figure 1

Anterior whole body ¹⁷⁷Lu-PSMA scan of a 72-year-old patient with metastasised castration-resistant prostate cancer. This demonstrates normal biodistribution in the nasal region, salivary glands, liver, and spleen gastrointestinal and urinary system, with multiple PSMA-avid metastases in the prostate bed, clavicle, sternum, clavicle, vertebrae, iliac bone, and femora. An excellent response to therapy was observed after 3 cycles of ¹⁷⁷Lu-PSMA-RLT with decrease in serum PSA level (from 63 to 4.25 ng/mL).